LEXARIA BIOSCIENCE CORP. Fair Value, Option, Credit Risk, Gains (Losses) on Assets
LEXARIA BIOSCIENCE CORP. (LEXX) reported Fair Value, Option, Credit Risk, Gains (Losses) on Assets of $482.05 thousand for the 12-month period ending 2025-08-31, per its 10-K filed 2025-11-28.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueOptionCreditRiskGainsLossesOnAssets · last filed 2025-11-28
- LEXARIA BIOSCIENCE CORP. fair value, option, credit risk, gains (losses) on assets for fiscal 2025 was $482.05K, a 61.98% decline from fiscal 2024.
- LEXARIA BIOSCIENCE CORP. fair value, option, credit risk, gains (losses) on assets for fiscal 2024 was $1.27M, a 1323.51% increase from fiscal 2023.
- LEXARIA BIOSCIENCE CORP. fair value, option, credit risk, gains (losses) on assets for fiscal 2023 was $89.06K, a 86.91% decline from fiscal 2022.
- LEXARIA BIOSCIENCE CORP. fair value, option, credit risk, gains (losses) on assets for fiscal 2022 was $680.51K.
| Period end | Fair Value, Option, Credit Risk, Gains (Losses) on Assets 12 month |
|---|---|
| 2025-08-31 | $482.05K 10-K · filed 2025-11-28 |
| 2024-08-31 | $1.27M 10-K · filed 2025-11-28 |
| 2023-08-31 | $89.06K 10-K · filed 2024-11-26 |
| 2022-08-31 | $680.51K 10-K · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |